The researchers tested their dual-action, cancer-killing vaccine in an advanced mouse model of glioblastoma, with promising results.
Taking advantage of this unique property, Shah’s team engineered living tumor cells using the gene editing tool CRISPR-Cas9 and repurposed them to release tumor cell killing agents. Also, the engineered tumor cells were designed to express factors that would make them easy for the immune system to spot, tag and remember, priming the immune system for a long-term anti-tumor response.
The researchers will soon be asking the FDA for approval for a Phase 1 trial. That would be for about 20 patients in the Boston area.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: ladailynews - 🏆 332. / 59 Read more »